The case for in silico trials
This e-book gives a comprehensive overview of nova’s industry-leading approach to drug development, examining the history of modeling in medicine, the regulatory landscape and current challenges to its adoption. Clinical trials are still the most expensive, risky, ethically debatable and time-consuming aspect of drug R&D, but there is a shift, accelerated by the COVID-19 pandemic, toward more ‘virtual’ trials.